• evo真人视讯

    Officials from the Ministry of Public Health of Thailand met with the Chairman of Shenzhen Cell Valley to discuss the industrial layout of cell therapy.

    Date:10-02  Hits:  Belong to:Corporate News

    On September 30, 2024, at the invitation of the Thai government, Dr. Shi Yuanyuan, Chairman of Shenzhen Cell Valley, led a delegation to Thailand and held high-level talks with officials from the Ministry of Public Health, Department of Health Service Support, at the Thai Government House. The meeting aimed to advance Shenzhen Cell Valley’s cell therapy industrial projects in Thailand and explore in-depth cooperation with local government authorities, medical institutions and universities in the field of cell therapy.

    Present at the meeting were:Dr. Samart Thirasak, Deputy Permanent Secretary of the Department of Health Service Support, Ministry of Public Health of Thailand;Dr. Kanyarat Kuisuwan, Deputy Director of the Medical Industry Promotion Department;Ms. Chayavee Khamwattanachi, Leader of the Assisted Reproductive Technology Unit, Department of Healing and Treatment;Dr. Shi Yuanyuan, Chairman of Shenzhen Cell Valley;

    Dr. Fu Yuchen, Assistant to the Chairman;and Dr. Sranyoo Chanate, Chief Executive Officer of Kluaynamthai Hospital Group, together with other partners.

    During the talks, Dr. Shi Yuanyuan elaborated on the leading advantages and market prospects of Shenzhen Cell Valley in cell therapy technologies, and expressed a strong desire to establish long-term strategic cooperation with medical and academic institutions in Thailand.Dr. Samart spoke highly of Shenzhen Cell Valley’s investment and technical cooperation plans, and pledged that the Thai government would provide comprehensive support and necessary policy conveniences for the smooth implementation of the project.

    In addition, the two sides conducted in-depth discussions on Shenzhen Cell Valley assisting Thailand in establishing a full-process regulatory system for cell therapy that meets international standards, particularly the introduction of accreditations from FACT (Foundation for the Accreditation of Cellular Therapy) and AABB (American Association of Blood Banks). This exchange laid a solid foundation for the policy standardization of Thailand’s cell therapy industry.

    The two sides also held constructive discussions on biomedical research and development, clinical research cooperation, and talent cultivation.

    This meeting has further deepened the mutual trust between Shenzhen Cell Valley and Thailand’s Ministry of Public Health, laying a solid foundation for future market expansion in Thailand.Our company sincerely appreciates the support from the Thai government and looks forward to reaching concrete cooperation agreements as soon as possible, so as to jointly promote the vigorous development of the cell therapy industry in Thailand.


    About Us
    Scan to follow our latest newsScan to follow our latest news
    Contact Us
    400-800-1266

    Working hours: Monday to Friday, 9:00-18:00

    Contact:Ms. Lai

    Email:laijiaqi@rodael.com

    Address:No. 1, Rongtian Road, Jinsha Community, Kengzi Street, Pingshan District, Shenzhen, China (Hepure Biomedical Ecological Park)

    Bottom Navigation
    Shenzhen Cell Valley Biopharmaceutical Co., Ltd.​​ is a comprehensive one-stop outsourcing service provider in China focused on the cell and gene therapy industry. It is also one of the first CRO/CDMO companies in the country to possess GMP industrial production capabilities for clinical-grade retroviral vectors . The company is a major public technical service platform construction project for CRO/CDMO in Shenzhen and is included among the city's latest announced "20+8" strategic emerging industry projects.Shenzhen Cell Valley has the capability for standardized and industrialized production of GMP-grade cell products such as CAR-T cells. Its primary production lines include those for various cell products like CAR-T, CAR-NK, CAR-M, γδT, TIL, and TCR-T. Additionally, the company operates production lines for various viral vectors, including RVV, LVV, non-viral vectors, and AAV, as well as for cellular raw materials used in producing therapeutics such as exosomes, genetically engineered antibodies, cytokines, oncolytic viruses, and vaccines.
     Copyright 粤ICP备2024168379号 互联网药品信息服务资格证书:(粤)-非经营性-2022-0426  Technical Support:YouDian Software